01.20.15
Johnson & Johnson sales for the fourth quarter of 2014 were $18.3 billion, a decrease of 0.6% as compared to the fourth quarter of 2013. Worldwide sales for the full-year were $74.3 billion, an increase of 4.2% versus 2013.
"2014 was a strong year for Johnson & Johnson, as we delivered solid financial results while continuing to make investments to accelerate growth for the long term. We have built significant momentum in our pharmaceutical business, are realizing the benefits of innovation, scale and breadth in our medical devices business and are continuing our market leadership with iconic brands in our consumer business," said Alex Gorsky, Chairman and Chief Executive Officer. "I am proud of our exceptional Johnson & Johnson colleagues who make our success possible with their commitment to advancing health and well-being for patients and consumers around the world."
Worldwide consumer sales of $14.5 billion for the full-year 2014 represented a decrease of 1.4% versus the prior year, consisting of an operational increase of 1.0% and a negative impact from currency of 2.4%. Domestic sales decreased 1.3%; international sales decreased 1.4%, which reflected an operational increase of 2.3% and a negative currency impact of 3.7%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 2.8%, domestic sales increased 3.1% and international sales increased 2.6%.*
Positive contributors to operational results were sales of products that included Aveeno and Neutrogean skin care as well as Listerine oral care, the firm noted.
Breaking down the numbers, worldwide baby care reported sales in the fourth quarter fell 10.4% and oral care sales worldwide fell 1.0%. Skin care sales in Q4 were down too, falling 1.4% as US sales rose 9.0% and international sales dropped 9.9%.
For the year, worldwide baby care sales fell 2.4%, skin care sales were up 1.5% and oral care sales posted a 1.5% gain.
"2014 was a strong year for Johnson & Johnson, as we delivered solid financial results while continuing to make investments to accelerate growth for the long term. We have built significant momentum in our pharmaceutical business, are realizing the benefits of innovation, scale and breadth in our medical devices business and are continuing our market leadership with iconic brands in our consumer business," said Alex Gorsky, Chairman and Chief Executive Officer. "I am proud of our exceptional Johnson & Johnson colleagues who make our success possible with their commitment to advancing health and well-being for patients and consumers around the world."
Worldwide consumer sales of $14.5 billion for the full-year 2014 represented a decrease of 1.4% versus the prior year, consisting of an operational increase of 1.0% and a negative impact from currency of 2.4%. Domestic sales decreased 1.3%; international sales decreased 1.4%, which reflected an operational increase of 2.3% and a negative currency impact of 3.7%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 2.8%, domestic sales increased 3.1% and international sales increased 2.6%.*
Positive contributors to operational results were sales of products that included Aveeno and Neutrogean skin care as well as Listerine oral care, the firm noted.
Breaking down the numbers, worldwide baby care reported sales in the fourth quarter fell 10.4% and oral care sales worldwide fell 1.0%. Skin care sales in Q4 were down too, falling 1.4% as US sales rose 9.0% and international sales dropped 9.9%.
For the year, worldwide baby care sales fell 2.4%, skin care sales were up 1.5% and oral care sales posted a 1.5% gain.